[go: up one dir, main page]

UY30641A1 - Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones - Google Patents

Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones

Info

Publication number
UY30641A1
UY30641A1 UY30641A UY30641A UY30641A1 UY 30641 A1 UY30641 A1 UY 30641A1 UY 30641 A UY30641 A UY 30641A UY 30641 A UY30641 A UY 30641A UY 30641 A1 UY30641 A1 UY 30641A1
Authority
UY
Uruguay
Prior art keywords
pirazol
pharmaceutically acceptable
acceptable salts
pyridins
derivatives
Prior art date
Application number
UY30641A
Other languages
English (en)
Inventor
Huifen Chen
Stephen Douglas Barrett
Kramer James Bernard
Mark Laurence Boys
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY30641A1 publication Critical patent/UY30641A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invencion proprciona compuestos de formula I, y sus sales farmacéuticamente aceptables, en la que R1, R2,R3, R4, R5, R6, y R7 tienen cualquiera de los valores definidos para ellos en la memoria descriptiva, y sus sales farmacéuticamente aceptables, que son utiles como agentes terapeuticos en el tratamiento de trastornos mediados por TGFB, incluyendo el cáncer y trastornos fibroticos. También se proporcionan composiciones farmacéuticas que comprenden uno o más compuestos de formula I.
UY30641A 2006-10-16 2007-10-12 Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones UY30641A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US85198206P 2006-10-16 2006-10-16

Publications (1)

Publication Number Publication Date
UY30641A1 true UY30641A1 (es) 2008-05-31

Family

ID=38962671

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30641A UY30641A1 (es) 2006-10-16 2007-10-12 Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones

Country Status (16)

Country Link
US (5) US7964612B2 (es)
EP (2) EP2074128B1 (es)
JP (1) JP5443988B2 (es)
KR (1) KR20090066297A (es)
CN (1) CN101528752A (es)
AR (1) AR063318A1 (es)
AU (1) AU2007311560B2 (es)
CA (1) CA2666603C (es)
CL (1) CL2007002916A1 (es)
ES (2) ES2559521T3 (es)
IL (1) IL197750A0 (es)
MX (1) MX2009003157A (es)
NO (1) NO20091247L (es)
TW (1) TW200825094A (es)
UY (1) UY30641A1 (es)
WO (1) WO2008047198A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2074128B1 (en) 2006-10-16 2013-08-14 Medicis Pharmaceutical Corporation Therapeutic pyrazolyl thienopyridines
US9855370B2 (en) 2008-01-08 2018-01-02 Yale University Compositions and methods for promoting patency of vascular grafts
MA32978B1 (fr) * 2008-12-29 2012-01-02 Sanofi Sa Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
FR2949468B1 (fr) * 2009-08-28 2011-09-30 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur preparation et leur application en therapeutique
PE20120416A1 (es) 2008-12-29 2012-05-08 Sanofi Sa Derivados de 2-piridin-2-il-pirazol-3(2h)-ona como activadores de hif y preparacion de los mismos
FR2940652B1 (fr) * 2008-12-29 2011-02-11 Sanofi Aventis Derives de 2-pyridin-2-yl-pyrazol-3(2h)-one,leur preparation et leur application en therapeutique
WO2010118063A2 (en) * 2009-04-06 2010-10-14 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
EP2448581B1 (en) 2009-06-29 2016-12-07 Agios Pharmaceuticals, Inc. Therapeutic compositions and related methods of use
KR101712035B1 (ko) 2009-06-29 2017-03-03 아지오스 파마슈티컬스 아이엔씨. 치료용 화합물 및 조성물
EP2557081A4 (en) * 2010-03-15 2013-04-10 Univ Hiroshima THIENOPYRIDINE DERIVATIVE, METHOD FOR ITS PRODUCTION AND ORGANIC SEMICONDUCTOR DEVICE THEREWITH
JP5743418B2 (ja) * 2010-04-09 2015-07-01 Ｏａｔアグリオ株式会社 新規なピラゾール化合物、その製造方法及び有害生物防除剤
ES2770575T3 (es) * 2010-10-28 2020-07-02 Pacira Pharmaceuticals Inc Formulación de liberación sostenida de un fármaco antiinflamatorio no esteroideo
AR084312A1 (es) 2010-12-16 2013-05-08 Genentech Inc Compuestos triciclicos inhibidores de la pi3k y composiciones farmaceuticas
US9221792B2 (en) 2010-12-17 2015-12-29 Agios Pharmaceuticals, Inc N-(4-(azetidine-1-carbonyl) phenyl)-(hetero-) arylsulfonamide derivatives as pyruvate kinase M2 (PMK2) modulators
CA2822432C (en) 2010-12-21 2019-09-24 Agios Pharmaceuticals, Inc. Bicyclic pkm2 activators
TWI549947B (zh) 2010-12-29 2016-09-21 阿吉歐斯製藥公司 治療化合物及組成物
CA2825028A1 (en) * 2011-02-09 2012-08-16 F. Hoffman-La Roche Ag Heterocyclic compounds as pi3 kinase inhibitors
WO2012151440A1 (en) 2011-05-03 2012-11-08 Agios Pharmaceuticals, Inc. Pyruvate kinase activators for use for increasing lifetime of the red blood cells and treating anemia
CN108451955B (zh) 2011-05-03 2022-02-01 安吉奥斯医药品有限公司 用于治疗的丙酮酸激酶活化剂
US9446175B2 (en) 2011-06-03 2016-09-20 Yale University Compositions and methods for treating and preventing neointimal stenosis
CN102660253B (zh) * 2012-03-07 2014-05-21 泰山医学院 一种吡唑啉衍生物类Ni2+荧光探针及其应用
EP3763367A1 (en) 2012-12-06 2021-01-13 Celgene Quanticel Research, Inc. Pyridine-pyrazole derivatives as histone demethylase inhibitors
WO2014139144A1 (en) 2013-03-15 2014-09-18 Agios Pharmaceuticals, Inc. Therapeutic compounds and compositions
JP2016522234A (ja) * 2013-06-20 2016-07-28 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ピリジルヒドラジンからピリジルピラゾール化合物及びその誘導体を製造するための方法
EP4344703A1 (en) 2015-06-11 2024-04-03 Agios Pharmaceuticals, Inc. Methods of using pyruvate kinase activators
EP3386556A4 (en) 2015-12-11 2019-07-31 Research Institute at Nationwide Children's Hospital SYSTEMS AND METHOD FOR OPTIMIZED PATIENT-SPECIFIC TISSUE-RENEWED TISSUE TRANSPLANTS
KR102434226B1 (ko) * 2016-06-30 2022-08-19 한미약품 주식회사 Alk5 억제제로서의 신규 피라졸 유도체 및 이의 용도
KR20190057108A (ko) * 2016-09-30 2019-05-27 인터셉트 파마슈티컬즈, 인크. 담즙산 유도체의 결정형
EP3541815A4 (en) 2016-11-18 2020-07-15 Pacira Pharmaceuticals, Inc. ZINC MELXICAM COMPLEX MICROPARTICLE MULTIVESICULAR LIPOSOME FORMULATIONS AND METHODS OF MAKING THE SAME
US20230321124A1 (en) * 2020-06-30 2023-10-12 Dermira, Inc. ROR gamma t Inhibitors and Topical Uses Thereof
JP2023542789A (ja) * 2020-09-28 2023-10-12 シチュアン ケルン－バイオテック バイオファーマシューティカル カンパニー リミテッド ピラゾール化合物並びにその調製方法及び使用
EP4333853A4 (en) * 2021-05-03 2025-03-26 Thirona Bio, Inc. Method for treating lung disease with an ALK-5 (TGF BETA R1) inhibition
IL316622A (en) * 2022-04-29 2024-12-01 Mannkind Corp Method and composition for treating lung diseases
US20250134875A1 (en) * 2023-10-25 2025-05-01 Thirona Bio, Inc. Formulations of alk-5 kinase inhibitors and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0102672D0 (en) * 2001-02-02 2001-03-21 Glaxo Group Ltd Compounds
UA80571C2 (en) * 2002-11-22 2007-10-10 Lilly Co Eli Quinolinyl-pyrrolopyrazoles
SE0300120D0 (sv) * 2003-01-17 2003-01-17 Astrazeneca Ab Novel compounds
CL2004000234A1 (es) * 2003-02-12 2005-04-15 Biogen Idec Inc Compuestos derivados 3-(piridin-2-il)-4-heteroaril-pirazol sustituidos, antagonistas de aik5 y/o aik4; composicion farmaceutica y uso del compuesto en el tratamiento de desordenes fibroticos como esclerodermia, lupus nefritico, cicatrizacion de herid
AR048669A1 (es) * 2004-03-03 2006-05-17 Syngenta Ltd Derivados biciclicos de bisamida
AU2005280167A1 (en) * 2004-08-31 2006-03-09 Biogen Idec Ma Inc. Pyrimidinylpyrazoles as TGF-beta inhibitors
EP1812450A2 (en) * 2004-11-10 2007-08-01 Eli Lilly And Company Tgf-beta inhibitors
EP2074128B1 (en) 2006-10-16 2013-08-14 Medicis Pharmaceutical Corporation Therapeutic pyrazolyl thienopyridines

Also Published As

Publication number Publication date
US20150175624A1 (en) 2015-06-25
ES2559521T3 (es) 2016-02-12
US9260450B2 (en) 2016-02-16
US9938289B2 (en) 2018-04-10
AR063318A1 (es) 2009-01-21
TW200825094A (en) 2008-06-16
US20080090861A1 (en) 2008-04-17
EP2527345A1 (en) 2012-11-28
CN101528752A (zh) 2009-09-09
US20160200735A1 (en) 2016-07-14
US7964612B2 (en) 2011-06-21
EP2074128A1 (en) 2009-07-01
KR20090066297A (ko) 2009-06-23
AU2007311560A1 (en) 2008-04-24
NO20091247L (no) 2009-04-23
CL2007002916A1 (es) 2008-04-18
AU2007311560B2 (en) 2011-04-21
WO2008047198A1 (en) 2008-04-24
MX2009003157A (es) 2009-04-03
JP2010506895A (ja) 2010-03-04
US20110224251A1 (en) 2011-09-15
ES2435430T3 (es) 2013-12-19
IL197750A0 (en) 2009-12-24
CA2666603A1 (en) 2008-04-24
EP2527345B1 (en) 2015-12-16
JP5443988B2 (ja) 2014-03-19
CA2666603C (en) 2013-08-06
US8455512B2 (en) 2013-06-04
EP2074128B1 (en) 2013-08-14
US9090625B2 (en) 2015-07-28
US20140031385A1 (en) 2014-01-30

Similar Documents

Publication Publication Date Title
UY30641A1 (es) Derivados de 2-[1h-pirazol-5-il] y de 2-[2h-pirazol-3-il]tieno[3,2-c]piridinas sustituidas, sus sales farmaceuticamente aceptables y aplicaciones
ECSP099728A (es) Compuestos amino-heterocíclicos
UY32391A (es) Compuestos amino-heterocíclicos
ECSP18083519A (es) Inhibidores de bromodominios
PE20151788A1 (es) Inhibidores de bromodominios tetraciclicos
ECSP10010335A (es) Pirrolo-pirimidinas y pirrolo-piridinas
DOP2005000064A (es) Nuevos compuestos
UY32138A (es) Amidas sustituidas del ácido 2-(2,6-dicloro-fenilamino)-6-fluoro-1-metil-1h-bencimidazol-5-carboxílico y sus sales farmacéuticamente aceptables
PA8627201A1 (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
UY30316A1 (es) Derivados sustituidos de benzamidas, nicotinamidas, propanamidas, acetamidas y carboxamidas n-(2-(piperidin-1-ilmetil)ciclohexil)sustituidas, procesos de preparacion, composiciones conteniéndolos y aplicaciones
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
CY1114140T1 (el) Ενωσεις 4-πυριδινονης και η χρηση αυτων για τον καρκινο
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
DE602006006712D1 (de) Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
ECSP088967A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
ECSP088966A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia
UY30363A1 (es) Derivados sustituidos de la n-(3-oxo-2,3-dihidro-1h-isoindol-4-il)-1-naftamida, procesos de preparacion, composiciones farmacéuticas y aplicaciones
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
CR10255A (es) "nuevas composiciones terapéuticas para el tratamiento o la prevención de trastornos psicóticos"
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
UY32016A (es) Compuesto de 1,6-dihidro-2h-3-oxa-6-aza-as-indaceno
UY30029A1 (es) Derivados de piperidina, sus sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolos y aplicaciones
DOP2002000386A (es) Agentes antibacterianos
ECSP088968A (es) Agonistas del receptor muscarínico que son efectivos en el tratamiento del dolor, la enfermedad de alzheimer y la esquizofrenia

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170727